Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers

Journal of Clinical Oncology

Volumn 27, Issue 31, 2009, Pages 5262-5269

  Lewis, Nancy L ^a   Lewis, Lionel D ^a   Eder, Joseph P ^a   Reddy, Nandi J ^a   Guo, Feng ^a   Pierce, Kristen J ^a   Olszanski, Anthony J ^a   Cohen, Roger B ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CP 868596; PLATELET DERIVED GROWTH FACTOR RECEPTOR; ANTINEOPLASTIC AGENT; PDGF RECEPTOR TYROSINE KINASE; PROTEIN KINASE INHIBITOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; DIARRHEA; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEMATURIA; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPERKALEMIA; HYPONATREMIA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; NAUSEA; NAUSEA AND VOMITING; PRIORITY JOURNAL; SIDE EFFECT; SOLID TUMOR; VOMITING; ADOLESCENT; CLINICAL TRIAL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; MIDDLE AGED; NEOPLASM; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; YOUNG ADULT;

EID: 70449707509     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.21.8487     Document Type: Article

References (15)

1. Pietras K, Sjoblom T, Rubin K, et al: PDGF receptors as cancer drug targets. Cancer Cell 3:439-443, 2003
2. Cao Y: Opinion: Emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis. Nat Rev Cancer 5:735-743, 2005
3. Ostman A, Heldin CH: PDGF receptors as targets in tumor treatment. Adv Cancer Res 97:247-274, 2007
4. Lewis NL: The platelet-derived growth factor receptor as a therapeutic target. Curr Oncol Rep 9:89-95, 2007
5. Pietras K, Ostman A, Sjoquist M, et al: Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 61: 2929-2934, 2001
6. Pietras K, Rubin K, Sjoblom T, et al: Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 62:5476-5484, 2002
7. Pietras K, Stumm M, Hubert M, et al: STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake. Clin Cancer Res 9:3779-3787, 2003
8. Lewis N, Eder JP, Guo F, et al: Phase 1 study of CP-868,596 an oral, highly specific PDGFR inhibitor. J Clin Oncol 25:144s, 2007 (suppl; abstr 3524)
9. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
10. Ratain MJ, Eckhardt SG: Phase II studies of modern drugs directed against new targets: If you are fazed, too, then resist RECIST. J Clin Oncol 22:4442-4445, 2004
11. Andrews PL, Sanger GJ: Abdominal vagal afferent neurones: An important target for the treatment of gastrointestinal dysfunction. Curr Opin Pharmacol 2:650-656, 2002
12. Demetri GD, von MM, Blanke CD, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347: 472-480, 2002
13. Demetri GD, van Oosterom AT, Garrett CR, et al: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 368:1329-1338, 2006
14. Sherman SI, Wirth LJ, Droz JP, et al: Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 359:31-42, 2008
15. Jayson GC, Parker GJ, Mullamitha S, et al: Blockade of platelet-derived growth factor receptorbeta by CDP860, a humanized, PEGylated di-Fab, leads to fluid accumulation and is associated with increased tumor vascularized volume. J Clin Oncol 23:973-981, 2005